Welcome

Pre-Open

RegMed Investors’ (RMi) pre-open: hop in the session, follow those bouncing share prices

January 22, 2021

It’s a short-term ride, pay-up, follow and slow walk the upside

Pre-open indication: 4 SELLs and 7 BUYs

What I provide is a trusted source of share pricing intelligence that ensures that investors are kept apprised of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!

Out and About

Precigen (PGEN) prices offering at $7.50 15 M share offering

January 22, 2021

PGEN closed down -$0.27 or -2.87% to $9.14 with a -$1.26 or -13.79% aftermarket indication

Proceeds from the offering, are expected to be approximately $112.5 million, excluding any exercise of the underwriters' option.

Wells Fargo Securities and Stifel are acting as joint book-running managers for the offering with JMP Securities acting as lead co-manager and H.C. Wainwright & Co. acting as co-manager.

Closing Bell

RegMed Investors’ (RMi) closing bell: bounce-back BUYs were up today

January 22, 2021

The roller-coaster creates sudden and extreme changes – it’s a question of fastening your emotions

Pre-open indication: 8 HITs and 3 MISS and the week in review

News: Ultragenyx Pharmaceutical (RARE +$4.85) The FDA has cleared the IND application for UX701, being evaluated for the treatment of Wilson Disease; a rare inherited disorder, in which excess copper builds up in the body. Its symptoms are typically related to the brain and liver.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investor profiting!

Are we here to make money or see share pricing erode as earnings LPS (loss-per-share) season is about to begin? Numbers based facts speak better then opinion as I see answers in numbers

Research Notes

Precigen (PGEN) prices offering at $7.50 15 M share offering

January 22, 2021

PGEN closed down -$0.27 or -2.87% to $9.14 with a -$1.26 or -13.79% aftermarket indication Proceeds from the offering, are expected to be approximately $112.5 million, excluding any exercise of the underwriters' option. Wells Fargo Securities and Stifel are acting as joint book-running managers for the offering with JMP Securities acting as lead co-manager and H.C. Wainwright & Co. acting as co-manager.

Caladrius Biosciences (CLBS) proposes $25 M Private Placement of 12.5 M shares plus warrants at a purchase price of $2.00

January 21, 2021

CLBS has dropping -$0.40 or -13.84% to $2.485 The warrants have an exercise price of $2.90 per share, are exercisable immediately and have a term of five and one-half years.

Editas Medicine (EDIT) proposes 3.5 million shares offering

January 19, 2021

EDIT closed down -$4.03 or -5.29% to $72.11 and has a negative -$1.11 or -1.54% aftermarket indication, so far J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the offering. Cowen and Credit Suisse are acting as book-runners.

Research Notes

January 22, 2021 Precigen (PGEN) prices offering at $7.50 15 M share offering PGEN closed down -$0.27 or -2.87% to $9.14 with a -$1.26 or -13.79% aftermarket indication Proceeds from the offering, are expected to be approximately $112.5 million, excluding any exercise of the underwriters' option. Wells Fargo Securities and Stifel are acting as joint book-running managers for the offering with JMP Securities acting as lead co-manager and H.C. Wainwright & Co. acting as co-manager. January 21, 2021 Caladrius Biosciences (CLBS) proposes $25 M Private Placement of 12.5 M shares plus warrants at a purchase price of $2.00 CLBS has dropping -$0.40 or -13.84% to $2.485 The warrants have an exercise price of $2.90 per share, are exercisable immediately and have a term of five and one-half years. January 19, 2021 Editas Medicine (EDIT) proposes 3.5 million shares offering EDIT closed down -$4.03 or -5.29% to $72.11 and has a negative -$1.11 or -1.54% aftermarket indication, so far J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the offering. Cowen and Credit Suisse are acting as book-runners. January 12, 2021 REGENXBIO (RGNX) closes 4.26 million share offering at $47.00 RGNX raised $230.3 million BofA Securities, Morgan Stanley and Barclays are acting as joint book-running managers of the offering while Raymond James is acting as lead manager of the offering. January 6, 2021 Fate Therapeutics (FATE) prices 4.42 million share offering at $85.50 per share ...with 257,310 warrants priced at $85.499 Representing a $376 million proceeds after expenses Wells Fargo Securities acted as lead manager for the offering, and Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. Jefferies, BofA Securities, SVB Leerink and Barclays acted as joint book-running managers for the offering.

Indication intelligence, analysis and sector perception

Weekend Recap

Earnings